Lupin gets USFDA nod to Methylprednisolone tablets to treat inflammation

The company has received approval from the US Food and Drug Administration (USFDA) to market Methylprednisolone tablets, a generic version of Pharmacia and Upjohn Company's Medrol tablets, Lupin said in a statement.

Mumbai: Mumbai-based drugmaker, Lupin recently said it has received approval from the US health regulator to market Methylprednisolone tablets used for treatment of inflammation in many conditions.

The company has received approval from the US Food and Drug Administration (USFDA) to market a generic version of Pharmacia and Upjohn Company's Medrol tablets, Lupin said in a statement.

Also Read: Lupin gets USFDA tentative approval for generic tablets to treat Erectile Dysfunction

The drug is indicated to treat endocrine and rheumatic disorders, among others.

As per IQVIA MAT December 2018 data, the company said, Methylprednisolone tablets had annual sales of around $ 114.3 million in the US.

Lupin was founded in 1968 by Desh Bandhu Gupta, then an Associate Professor at BITS-Pilani, Rajasthan. Gupta died on 26 June 2017 and was replaced as chairman by his wife, Manju Deshbandhu Gupta.

The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

Also Read: Relief to Lupin: High court removes ban its diabetes drug Gluconorm P 30